Products with Anti-platelet aggregation bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3555 | Procurcumenol |
| 1. Procurcumenol is inhibitors of Nitric Oxide. 2. Procurcumenol and epicurcumenol have inhibitory effects on release of tumor necrosis factor-a (TNF-a). | |
| BCN3559 | Curcolone |
| 1. Curcolone exhibits inhibition against collagen-induced platelet aggregation at 100 uM, it also inhibit arachidonic acid (AA)-induced platelet aggregation at 100 uM. | |
| BCN3571 | Broussoflavonol F |
| 1. Broussoflavonol F has antiplatelet effect, is partially due to an inhibitory effect on cyclooxygenase, can inhibit arachidonic acid (AA)-induced platelet aggregation. 2. Broussoflavonol F shows inhibitory activities on mushroom tyrosinase. 3. Broussoflavonol F shows radical scavenging against 2,2-diphenyl-1-picrylhydrazyl (DPPH), the IC50 value of 708.54 uM. 4. Broussoflavonol F exhibits moderate cytotoxic activities against five human cancer cells with the IC50 value of 0.41-7.2 ug/mL. | |
| BCN3627 | Kadsulignan L |
| 1. Kadsulignan L shows in vitro antiviral effects on hepatitis B virus. 2. Kadsulignan L shows moderate platelet-activating factor (PAF) antagonistic activities with the IC50 value of 2.6 x 10(-5) M. | |
| BCN3671 | Loureirin A |
| Loureirin A has an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling. Loureirin A activates Wnt/-catenin pathway and promotes hair follicle stem cells (FSCs)-seeded tissue-engineered skin to repair skin wound.The molecular mechanism of Loureirin A and Wnt signaling pathway mediated anti- hepatic fibrosis and anti- angiogenesis may involve down- regulation the expression of Frizzled- 4,inhibiting the synthesis and secretion of α- SMA,TGF- β1and the proliferation of HSCs. | |
